Cardiovascular and Renal Effects of the β-Blocker SE2395 in Conscious Normotensive Dogs

Walker, Benjimen R.; Erickson, A. L.; Prost, J F; Rochat, Catherine; Burke, Thomas J.

doi:10.1097/00005344-198511000-00029

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such a hypothesis has been proposed previously by Walker et al [24], who reported similar findings with tertatolol. This action could be due to reduced effectiveness of renal sympathetic activity secondary to the (3-blocking action of tertatolol [25].…”

Section: Discussionsupporting

confidence: 84%

Renal Hemodynamic Effects of Tertatolol Compared with Those of Propranolol in the Conscious Dog

Laubie

Prost²,

Rochat³

1986

Am J Nephrol

View full text Add to dashboard Cite

Experiments were performed in which the effects of two β-blockers, tertatolol [dl-(hydroxy-2’-t-butyl-amino-3’-propyloxy)-8-thiochroman hydrochloride] and propranolol, on mean arterial pressure (MAP), heart rate (HR), and renal function were studied in the conscious sodium-replete dog. In all experiments renal function was evaluated from the effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) assessed respectively by measurement of p-aminohippurate and creatinine clearances. These parameters were measured during two 30-min control periods, after which two further measurements were performed over a similar time period, after intravenous administration of either propranolol (0.5 mg·kg^-1; n = 8) or tertatolol (0.05 mg·kg^-1; n = 8), these two doses being of equivalent β-adrenoceptor antagonist activity. Administration of propranolol and tertatolol did not change MAP but induced a significant and comparable decrease in HR. After propranolol a significant decrease in ERPF was observed, without any change in GFR or sodium excretion. In contrast, administration of tertatolol resulted in no modification of ERPF, a slight but significant increase in GFR, and a significant increase in sodium and potassium excretion. These results suggest that tertatolol and propranolol though acting similarly on systemic parameters have different effects on renal hemodynamics in the conscious dog.

show abstract

Section: Discussionsupporting

confidence: 84%

Renal Hemodynamic Effects of Tertatolol Compared with Those of Propranolol in the Conscious Dog

Laubie

Prost²,

Rochat³

1986

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…The fall in PRA was similar in both groups of patients and PGE2 urinary excretion also remained unchanged in both groups. A similar absence of effect o f tertatolol on PG E2 urinary excretion was also observed by Walker et al [ 18] in normotensive dogs.…”

Section: Discussionsupporting

confidence: 82%

“…The fact, however, that both RPF and GFR increased in parallel as was also demonstrated in our previous study [11] and in that of Walker et al [ 18], gives some indirect evidence as to the site o f action o f tertatolol. An effect on mesangial cell contraction seems unlikely since Brondeau et al [22] showed that the diameter o f isolated rat glomeruli did not change in the presence of tertatolol (0.03-3 \aM).…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Renal Hemodynamic Effects of Tertatolol in Essential Hypertension

et al. 1986

View full text Add to dashboard Cite

Tertatolol, a new β-blocker, and propranolol, considered a reference β-blocker, were given orally (5 and 160 mg slow release, respectively) for 15 days to two groups of patients with essential hypertension in order to compare their effects on renal hemodynamics. Systolic and diastolic blood pressure, heart rate, and erect plasma renin activity fell significantly in both groups while prostaglandin E₂ urinary excretion was unchanged. Tertatolol administration produced increases in glomerular filtration rate, as shown by inulin clearance (+8.9%; p = 0.038) and renal plasma flow, as shown by paraaminohippurate clearance (+13.0%; p = 0.007). In contrast, propranolol administration resulted in a slight decrease in glomerular filtration rate (-2.8%; not significant) and a fall in renal plasma flow (-13.4%; p < 0.001). Comparison between both treatments showed that glomerular filtration rate and renal plasma flow were higher in the patients treated with tertatolol than in those treated with propranolol whereas filtration fraction was lower, which suggests that tertatolol causes a vasodilation of the glomerular afferent arteriole. These results demonstrate that in contrast to propranolol (160 mg), and despite both drugs exhibiting a comparable antihypertensive activity, tertatolol (5 mg) does not alter but even improves renal perfusion in hypertensive patients.

show abstract

“…It also has some pecu liar properties regarding renal hemodynamics. Laubie et al [29] and Walker et al [30] have shown that renal plasma flow measured by paraaminohippurate clearance and GFR measured by inulin clearance are unaffected by intravenous administration of tertatolol [29,30]. In spontaneously hypertensive rats, Struyker-Boudier et al [31] have shown that tertatolol induces a reduction of renal vascular resistance.…”

Section: Discussionmentioning

confidence: 99%

Effects of Tertatolol in Hypertensive Patients with Chronic Renal Failure

Beaufils¹,

Lantz²,

Paillard³

et al. 1986

Am J Nephrol

View full text Add to dashboard Cite

Chronic renal failure (CRF) is often associated with hypertension, as a cause or a consequence. We studied the changes in blood pressure (BP), heart rate (HR), renal function (as measured by creatinine clearance), and plasma renin activity (PRA) in 19 hypertensive patients with CRF before, during and after oral administration once a day for at least 30 days of 5 mg tertatolol, a new β-blocker. All patients were free of any antihypertensive medication for at least 1 month before administration of tertatolol. The dose of tertatolol given in this study was the same as that commonly used in patients with normal renal function. From day 0 to day 30 of tertatolol, measurements in the supine position were as follows: systolic BP (SBP) decreased from 168.4 ± 4.6 to 145.3 ± 4.3 mm Hg (p < 0.01); diastolic BP (DBP) decreased from 106.1 ± 2.4 to 87.1 ± 2.0 mm Hg (p < 0.01); HR decreased from 77.9 ± 1.6 to 63.2 ± 1.7 b.p.m. (p < 0.01); PRA decreased from 1.816 ± 0.521 to 1.052 ± 0.323 ng/ml/h (p < 0.01). Creatinine clearance remained stable: 37.1 ± 4.1 versus 37.1 ± 4.7 ml/min/1.73 m² (not significant). Similar results (for SBP, DBP, HR and PRA) were obtained in the erect position. It is concluded that tertatolol in hypertensive patients with CRF: (1) significantly lowers BP and HR without excessive bradycardia, (2) significantly lowers PRA, the most important decrease being observed for the highest initial PRA, (3) does not alter renal fuction, and (4) has a good clinical acceptability.

show abstract

Cardiovascular and Renal Effects of the β-Blocker SE2395 in Conscious Normotensive Dogs

Cited by 7 publications

References 0 publications

Renal Hemodynamic Effects of Tertatolol Compared with Those of Propranolol in the Conscious Dog

Renal Hemodynamic Effects of Tertatolol Compared with Those of Propranolol in the Conscious Dog

Renal Hemodynamic Effects of Tertatolol in Essential Hypertension

Effects of Tertatolol in Hypertensive Patients with Chronic Renal Failure

Contact Info

Product

Resources

About